Liquidia: Yutrepia's Launch Momentum Is Approaching A Ceiling (Rating Downgrade)

Liquidia delivered strong Q1 results, with Yutrepia net sales up 44% sequentially and a third consecutive profitable quarter. LQDA now commands a 23% share of the inhaled prostacyclin segment, but further market share gains are likely capped by entrenched competitors and limited product differentiation. At a near $5 billion market cap and 9x run-rate revenue, the current valuation assumes sustained momentum and peak Yutrepia sales north of $1.2 billion, which appears optimistic.